Population pharmacokinetics and dosing optimization of imipenem in Chinese elderly patients
- PMID: 39850576
- PMCID: PMC11754279
- DOI: 10.3389/fphar.2024.1524272
Population pharmacokinetics and dosing optimization of imipenem in Chinese elderly patients
Erratum in
-
Corrigendum: Population pharmacokinetics and dosing optimization of imipenem in Chinese elderly patients.Front Pharmacol. 2025 Feb 14;16:1565995. doi: 10.3389/fphar.2025.1565995. eCollection 2025. Front Pharmacol. 2025. PMID: 40028166 Free PMC article.
Abstract
Objectives: To assess the pharmacokinetics and pharmacodynamics of imipenem in a retrospective cohort of hospitalized Chinese older patients.
Methods: A population pharmacokinetic (PPK) model was constructed utilizing a nonlinear mixed-effects modeling approach. The final model underwent evaluation through bootstrap resampling and visual predictive checks. Additionally, a population pharmacokinetic and pharmacodynamic analysis was conducted employing Monte Carlo simulations to investigate the impact of commonly used dosing regimens (0.25 g every 6 h, 0.5 g every 6 h, 0.5 g every 8 h, 1 g every 6 h, 1 g every 8 h, and 1 g every 12 h) on the likelihood of achieving the target therapeutic outcomes.
Results: A total of 370 observations available from 142 patients were incorporated in the PPK model. A two-compartment PPK model with linear elimination best predicted the imipenem plasma concentrations, with the creatinine clearance as a significant covariate of clearance. Typical estimates for clearance, inter-compartmental clearance, central and peripheral volume were 13.1 L·h-1, 11.9 L·h-1, 11.7 L, 29.3 L, respectively.
Conclusion: The pharmacokinetics of imipenem in elderly patients were effectively characterized by the established PPK model, which includes creatinine clearance as a key covariate. This research will enhance our understanding of imipenem elimination and support precision dosing in this patient demographic.
Keywords: Monte Carlo; dosing optimization; elderly patients; imipenem; population pharmacokinetics.
Copyright © 2025 Wang, Fang, Luo, Jin and Zhu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



References
-
- Abdulla A., Ewoldt T. M. J., Purmer I. M., Muller A. E., Gommers D., Endeman H., et al. (2021). A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients. Expert Opin. Drug Metab. Toxicol. 17, 359–368. 10.1080/17425255.2021.1879049 - DOI - PubMed
LinkOut - more resources
Full Text Sources